# TVTX catalysts: Travere Therapeutics, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/tvtx/catalysts

> Travere Therapeutics, Inc. (TVTX) has 7 upcoming catalysts. The next is the FILSPARI (sparsentan) topline data readout, Mar to Jun 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only, half-year only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Travere Therapeutics, Inc. |
| Ticker | TVTX (Nasdaq) |
| SEC CIK | 1438533 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/tvtx |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| February 17, 2023 | [FILSPARI (sparsentan) FDA approval](https://sec-api.dev/pdufa/sparsentan) | TVTX |  | completed, approved | "Filspari \| sparsentan \| 2/17/2023 \| To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progressionDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023)) |
| May 2023 | [Pegtibatinase topline data readout](https://sec-api.dev/pdufa/pegtibatinase) | TVTX |  | completed, positive | "In May 2023, we announced positive topline results from the sixth cohort of the Phase 1/2 COMPOSE Study, which was initiated to inform and refine formulation work for future development and commercial purposes and to further evaluate the dose response curve for pegtibatinase, and to further inform our pivotal development program to ultimately support potential approval of pegtibatinase for the treatment of HCU." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1438533/000143853326000077/tvtx-20260930.htm)) |
| Sep 2024 | [FILSPARI (sparsentan) FDA approval](https://sec-api.dev/pdufa/sparsentan) | TVTX | primary IgAN | completed, approved | "Our ability to generate significant product revenues and to achieve commercial success in the near-term will depend almost entirely on our ability to successfully commercialize our products in the United States, including FILSPARI (sparsentan) to slow kidney function decline in adults with primary IgAN who are at risk of disease progression, which was granted full approval by the FDA in September 2024, and FILSPARI (sparsentan) to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis ("FSGS") without nephrotic syndrome, which was granted full (traditional) approval by the FDA in April 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1438533/000143853326000077/tvtx-20260930.htm)) |
| September 5, 2024 | [FILSPARI (sparsentan) label expansion decision](https://sec-api.dev/pdufa/sparsentan) | TVTX |  | completed, approved | "NDA216403 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20240905, review_priority PRIORITY; sponsor_name TRAVERE; product FILSPARI (SPARSENTAN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216403%22)) |
| Q1 2025 | [FILSPARI (sparsentan) NDA/BLA submission](https://sec-api.dev/pdufa/sparsentan) | TVTX |  | scheduled | "•expectations regarding the potential for sparsentan in focal segmental glomerulosclerosis (FSGS) and related matters, including our planned submission of a supplemental new drug application (sNDA) for FSGS around the end of the first quarter of 2025;" ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1438533/000143853325000010/tvtx-20241231.htm)) |
| January 13, 2025 | [Travere Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tvtx/catalysts) | TVTX |  | completed | "The Company expects to announce complete full year 2024 financial results and provide a corporate update in February." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1438533/000143853325000002/aex991_2024q4xearningsprex.htm)) |
| February 11, 2025 | [FILSPARI (sparsentan) NDA/BLA submission](https://sec-api.dev/pdufa/sparsentan) | TVTX |  | completed | "On February 11, 2025, we announced that we had completed a Type C meeting with the FDA and on March 17, 2025, we announced that we had submitted an sNDA to the FDA seeking priority review for traditional approval of FILSPARI for the treatment of FSGS." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1438533/000143853325000026/tvtx-20250331.htm)) |
| February 20, 2025 | [Travere Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tvtx/catalysts) | TVTX |  | completed | "Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1438533/000143853325000008/aex991_2024q4x10xkearnings.htm)) |
| March 17, 2025 | [FILSPARI (sparsentan) NDA/BLA submission](https://sec-api.dev/pdufa/sparsentan) | TVTX | focal segmental glomerulosclerosis | completed | "On March 17, 2025, Travere Therapeutics, Inc. (the "Company") announced that it has submitted a supplemental New Drug Application ("sNDA") to the U.S. Food and Drug Administration ("FDA") seeking priority review for traditional approval of FILSPARI® (sparsentan) for the treatment of focal segmental glomerulosclerosis ("FSGS")." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1438533/000143853325000012/tvtx-20250317.htm)) |
| May 15, 2025 | [FILSPARI (sparsentan) NDA/BLA acceptance](https://sec-api.dev/pdufa/sparsentan) | TVTX | focal segmental glomerulosclerosis | completed | "On May 15, 2025, Travere Therapeutics, Inc. (the "Company") announced that the U.S. Food and Drug Administration ("FDA") has accepted its supplemental New Drug Application ("sNDA") for traditional approval of FILSPARI® (sparsentan) for the treatment of focal segmental glomerulosclerosis ("FSGS")." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1438533/000143853325000032/tvtx-20250515.htm)) |
| 2H 2025 | [Repagermanium interim data readout](https://sec-api.dev/pdufa/repagermanium) | TVTX |  | scheduled | "Dimerix has indicated that an interim analysis will be made available in the second half of 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1438533/000143853325000010/tvtx-20241231.htm)) |
| Aug 2025 | [FILSPARI (sparsentan) FDA approval](https://sec-api.dev/pdufa/sparsentan) | TVTX |  | completed, approved | "In August 2025, we announced that the FDA approved updated REMS labeling for FILSPARI, reducing the frequency of liver function monitoring to every three months from the onset of treatment with FILSPARI, and removing the embryo-fetal toxicity monitoring requirement from the REMS." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1438533/000143853326000077/tvtx-20260930.htm)) |
| August 6, 2025 | [Travere Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tvtx/catalysts) | TVTX |  | completed | "Travere Therapeutics Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1438533/000143853325000045/a2025q2_8-kxex991.htm)) |
| August 27, 2025 | [FILSPARI (sparsentan) label expansion decision](https://sec-api.dev/pdufa/sparsentan) | TVTX |  | completed, approved | "NDA216403 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20250827, review_priority STANDARD; sponsor_name TRAVERE; product FILSPARI (SPARSENTAN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216403%22)) |
| August 28, 2025 | [FILSPARI (sparsentan) NDA/BLA acceptance](https://sec-api.dev/pdufa/sparsentan) | TVTX |  | scheduled | "Received 693 new patient start forms for FILSPARI® (sparsentan) in the fourth quarter of 2024; approximately $50 million in preliminary net product sales of FILSPARI for the fourth quarter sNDA requesting modification of liver monitoring for FILSPARI in IgAN accepted for review by FDA; PDUFA target action date of August 28, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1438533/000143853325000002/aex991_2024q4xearningsprex.htm)) |
| August 28, 2025 | [FILSPARI (sparsentan) PDUFA date](https://sec-api.dev/pdufa/sparsentan) | TVTX |  | completed, approved | "•The FDA assigned a PDUFA target action date of August 28, 2025, to the Company's supplemental New Drug Application (sNDA) requesting modification of liver monitoring for FILSPARI in IgAN." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1438533/000143853325000008/aex991_2024q4x10xkearnings.htm)) |
| Sep 2025 | [FILSPARI (sparsentan) FDA advisory committee meeting](https://sec-api.dev/pdufa/sparsentan) | TVTX |  | scheduled | "In September 2025, following further review of the sNDA, the FDA informed us that an advisory committee meeting is no longer needed." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1438533/000143853325000056/tvtx-20250930.htm)) |
| Q4 2025 | [FILSPARI (sparsentan) topline data readout](https://sec-api.dev/pdufa/sparsentan) | TVTX | IgAN in Japan | scheduled | "•The Company's partner, Renalys Pharma, Inc., expects topline results from its registrational Phase 3 clinical trial of sparsentan for the treatment of IgAN in Japan in the fourth quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1438533/000143853325000055/a2025q3_8-kxex991.htm)) |
| October 30, 2025 | [Travere Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tvtx/catalysts) | TVTX |  | completed | "Travere Therapeutics Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1438533/000143853325000055/a2025q3_8-kxex991.htm)) |
| 2026 | [FILSPARI (sparsentan) NDA/BLA submission](https://sec-api.dev/pdufa/sparsentan) | TVTX |  | scheduled | "•In 2026, the Company's partner, Chugai Pharmaceutical, expects to submit a New Drug Application for sparsentan in Japan." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1438533/000143853326000041/a2026q1_8-kxex991.htm)) |
| January 12, 2026 | [Travere Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tvtx/catalysts) | TVTX |  | completed | "The Company will present at the 44th Annual J.P. Morgan Healthcare Conference today at 4:30 p.m. PT, and expects to announce complete full year 2025 financial results and provide a corporate update in February." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1438533/000143853326000003/aex991_2025q4xearningsprex.htm)) |
| January 13, 2026 | [FILSPARI (sparsentan) PDUFA date](https://sec-api.dev/pdufa/sparsentan) | TVTX |  | scheduled | "•The Company's PDUFA target action date for its sNDA seeking full approval for FILSPARI in FSGS is January 13, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1438533/000143853326000003/aex991_2025q4xearningsprex.htm)) |
| February 19, 2026 | [Travere Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tvtx/catalysts) | TVTX |  | completed | "Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1438533/000143853326000013/aex991_2025q4x10xkearnings.htm)) |
| April 13, 2026 | [FILSPARI (sparsentan) FDA approval](https://sec-api.dev/pdufa/sparsentan) | TVTX |  | completed, approved | "On April 13, 2026, Travere Therapeutics, Inc. (the "Company") announced that the U.S. Food and Drug Administration ("FDA") has approved FILSPARI® (sparsentan) to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis ("FSGS") without nephrotic syndrome." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1438533/000143853326000032/tvtx-20260413.htm)) |
| April 13, 2026 | [Travere Therapeutics, Inc. PDUFA date](https://sec-api.dev/companies/tvtx/catalysts) | TVTX |  | scheduled | "In January 2026, we announced that the FDA extended the review timeline for the sNDA, and the new PDUFA target action date is April 13, 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1438533/000143853326000014/tvtx-20251231.htm)) |
| April 13, 2026 | [FILSPARI (sparsentan) PDUFA date](https://sec-api.dev/pdufa/sparsentan) | TVTX |  | completed, approved | "PDUFA target action date for FILSPARI in FSGS is April 13, 2026; Company positioned for a successful commercial launch, if approved" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1438533/000143853326000013/aex991_2025q4x10xkearnings.htm)) |
| April 13, 2026 | [FILSPARI (sparsentan) label expansion decision](https://sec-api.dev/pdufa/sparsentan) | TVTX |  | completed, approved | "NDA216403 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20260413, review_priority STANDARD; sponsor_name TRAVERE; product FILSPARI (SPARSENTAN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA216403%22)) |
| May 4, 2026 | [Travere Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tvtx/catalysts) | TVTX |  | completed | "Travere Therapeutics Reports First Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1438533/000143853326000041/a2026q1_8-kxex991.htm)) |
| Jun 2026 | [FILSPARI (sparsentan) NDA/BLA submission](https://sec-api.dev/pdufa/sparsentan) | TVTX |  | completed | "•In June 2026, the Company's partner, Chugai Pharmaceutical, submitted a New Drug Application for sparsentan in Japan." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1438533/000143853326000062/a2026q2_8-kxex991.htm)) |
| August 4, 2026 | [Travere Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tvtx/catalysts) | TVTX |  | completed | "Travere Therapeutics Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1438533/000143853326000062/a2026q2_8-kxex991.htm)) |
| November 2, 2026 | [Travere Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tvtx/catalysts) | TVTX |  | completed | "Travere Therapeutics Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1438533/000143853326000074/a2026q3_8-kxex991.htm)) |
| Mar to Jun 2027 | [FILSPARI (sparsentan) topline data readout](https://sec-api.dev/pdufa/sparsentan) | TVTX | Focal Segmental Glomerulosclerosis; Minimal Change Disease; Immunoglobulin A Nephropathy | scheduled | "NCT05003986 (Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03-12 (ESTIMATED); Lead Sponsor Travere Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05003986)) |
| March 2027 | [FILSPARI (sparsentan) primary completion](https://sec-api.dev/pdufa/sparsentan) | TVTX | Focal Segmental Glomerulosclerosis; Minimal Change Disease; Immunoglobulin A Nephropathy | scheduled | "NCT05003986 (Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03-12 (ESTIMATED); Lead Sponsor Travere Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05003986)) |
| 2H 2027 | [FILSPARI (sparsentan) topline data readout](https://sec-api.dev/pdufa/sparsentan) | TVTX |  | scheduled | "•In April 2026, the Company dosed the first new patient following the study restart, with topline data anticipated in 2H 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1438533/000143853326000041/a2026q1_8-kxex991.htm)) |
| August 2027 | [Pegtibatinase primary completion](https://sec-api.dev/pdufa/pegtibatinase) | TVTX | Homocystinuria | scheduled | "NCT06247085 (Pegtibatinase as a Treatment for Participants With Classical Homocystinuria (HCU) Receiving Standard of Care Treatment): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Travere Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06247085)) |
| Aug to Nov 2027 | [Pegtibatinase topline data readout](https://sec-api.dev/pdufa/pegtibatinase) | TVTX | Homocystinuria | scheduled | "NCT06247085 (Pegtibatinase as a Treatment for Participants With Classical Homocystinuria (HCU) Receiving Standard of Care Treatment): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Travere Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06247085)) |
| August 2030 | [Pegtibatinase primary completion](https://sec-api.dev/pdufa/pegtibatinase) | TVTX | Homocystinuria | scheduled | "NCT06431893 (A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE) (ENSEMBLE)): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2030-08 (ESTIMATED); Lead Sponsor Travere Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06431893)) |
| Aug to Nov 2030 | [Pegtibatinase topline data readout](https://sec-api.dev/pdufa/pegtibatinase) | TVTX | Homocystinuria | scheduled | "NCT06431893 (A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE) (ENSEMBLE)): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2030-08 (ESTIMATED); Lead Sponsor Travere Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06431893)) |

## Drugs

- [Pegtibatinase](https://sec-api.dev/pdufa/pegtibatinase): Homocystinuria
- [Repagermanium](https://sec-api.dev/pdufa/repagermanium): 
- [FILSPARI (sparsentan)](https://sec-api.dev/pdufa/sparsentan): primary igan, igan in japan, focal segmental glomerulosclerosis, iga nephropathy in japan

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/tvtx/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "TVTX catalysts: Travere Therapeutics, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/tvtx/catalysts

```bibtex
@misc{secapidev_companies_tvtx_catalysts_20261116,
  title        = {TVTX catalysts: Travere Therapeutics, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/tvtx/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_tvtx_catalysts_20261116","title":"TVTX catalysts: Travere Therapeutics, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/tvtx/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
